ALK is altered in 5.43% of non-squamous non-small cell lung carcinoma patients [2].

ALK is an inclusion eligibility criterion in 3 clinical trials for non-squamous non-small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ALK status and non-squamous non-small cell lung carcinoma as inclusion criteria, 3 are phase 2 (3 open) [3].

BRAF is altered in 5.51% of non-squamous non-small cell lung carcinoma patients [2].

BRAF is an inclusion eligibility criterion in 2 clinical trials for non-squamous non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

EGFR is altered in 25.27% of non-squamous non-small cell lung carcinoma patients [2].

EGFR is an inclusion eligibility criterion in 15 clinical trials for non-squamous non-small cell lung carcinoma, of which 15 are open and 0 are closed. Of the trials that contain EGFR status and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 2 (5 open), 7 are phase 3 (7 open), and 1 is phase 4 (1 open) [3].

ERBB2 is altered in 4.28% of non-squamous non-small cell lung carcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 5 clinical trials for non-squamous non-small cell lung carcinoma, of which 5 are open and 0 are closed. Of the trials that contain ERBB2 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [3].

KEAP1 is altered in 13.78% of non-squamous non-small cell lung carcinoma patients [2].

KEAP1 is an inclusion eligibility criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KEAP1 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KRAS is altered in 32.43% of non-squamous non-small cell lung carcinoma patients [2].

KRAS is an inclusion eligibility criterion in 3 clinical trials for non-squamous non-small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS status and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) and 1 is phase 3 (1 open) [3].

MET is altered in 5.21% of non-squamous non-small cell lung carcinoma patients [2].

MET is an inclusion eligibility criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NFE2L2 is altered in 1.62% of non-squamous non-small cell lung carcinoma patients [2].

NFE2L2 is an inclusion eligibility criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NFE2L2 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RET is altered in 3.33% of non-squamous non-small cell lung carcinoma patients [2].

RET is an inclusion eligibility criterion in 3 clinical trials for non-squamous non-small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RET status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) and 2 are phase 3 (2 open) [3].

ROS1 is altered in 4.1% of non-squamous non-small cell lung carcinoma patients [2].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].